Laboratory Co. of America - LH Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $243.50
  • Forecasted Upside: 18.36%
  • Number of Analysts: 14
  • Breakdown:
  • 0 Sell Ratings
  • 3 Hold Ratings
  • 11 Buy Ratings
  • 0 Strong Buy Ratings
▼ -0.77 (-0.37%)

This chart shows the closing price for LH by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Laboratory Co. of America Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for LH and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for LH

Analyst Price Target is $243.50
▲ +18.36% Upside Potential
This price target is based on 14 analysts offering 12 month price targets for Laboratory Co. of America in the last 3 months. The average price target is $243.50, with a high forecast of $270.00 and a low forecast of $210.00. The average price target represents a 18.36% upside from the last price of $205.73.

This chart shows the closing price for LH for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Moderate Buy

The current consensus among 14 contributing investment analysts is to moderate buy stock in Laboratory Co. of America. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 11 buy ratings
  • 3 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 11 buy ratings
  • 3 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 11 buy ratings
  • 3 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 11 buy ratings
  • 3 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 11 buy ratings
  • 3 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 11 buy ratings
  • 3 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 11 buy ratings
  • 3 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 11 buy ratings
  • 3 hold ratings
  • 0 sell ratings

Latest Recommendations

  • 0 strong buy ratings
  • 11 buy ratings
  • 3 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/25/2024ArgusUpgradeHold ➝ Buy$250.00Low
2/26/2024Leerink PartnrsReiterated RatingOutperformLow
2/26/2024SVB LeerinkInitiated CoverageOutperform$260.00Low
2/9/2024Evercore ISIInitiated CoverageIn-Line$240.00Low
1/3/2024BarclaysInitiated CoverageEqual Weight$222.00Low
11/17/2023JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$259.00 ➝ $261.00Low
10/31/2023MizuhoLower TargetBuy ➝ Buy$257.00 ➝ $230.00Low
9/21/2023Bank of AmericaLower TargetBuy ➝ Buy$238.00 ➝ $230.00Low
9/18/2023UBS GroupLower Target$255.00 ➝ $250.00Low
9/18/2023Robert W. BairdLower TargetOutperform ➝ Outperform$251.00 ➝ $237.00Low
9/15/2023MizuhoReiterated RatingBuy ➝ Buy$257.00Low
9/15/2023Truist FinancialReiterated RatingBuy ➝ Buy$270.00Low
9/6/2023HSBCInitiated CoverageHold$210.00Low
8/14/2023Wells Fargo & CompanyLower TargetOverweight ➝ Overweight$290.00 ➝ $270.00Low
8/3/2023Morgan StanleyLower TargetOverweight ➝ Overweight$285.00 ➝ $260.00Low
8/2/2023Credit Suisse GroupLower TargetOutperform ➝ Outperform$247.41 ➝ $231.00Low
7/31/2023Robert W. BairdLower TargetOutperform ➝ Outperform$255.00 ➝ $251.00Low
7/28/2023Truist FinancialLower TargetBuy$275.00 ➝ $270.00Low
5/16/2023MizuhoLower Target$277.00 ➝ $257.00Low
5/1/2023Truist FinancialLower Target$285.00 ➝ $275.00Low
4/26/2023Deutsche Bank AktiengesellschaftLower Target$265.00 ➝ $240.00Low
4/26/2023CitigroupLower Target$260.00 ➝ $235.00Low
3/13/2023Credit Suisse GroupLower TargetOutperform$304.00 ➝ $288.00Low
2/21/2023Credit Suisse GroupLower TargetOutperform$305.00 ➝ $304.00Low
2/21/2023Wells Fargo & CompanyLower TargetOverweight$315.00 ➝ $290.00Low
2/17/2023Truist FinancialBoost TargetBuy$275.00 ➝ $285.00Low
2/17/2023CitigroupBoost TargetNeutral$250.00 ➝ $260.00Low
2/17/2023Robert W. BairdBoost TargetOutperform$300.00Low
2/17/2023MizuhoBoost TargetBuy$250.00 ➝ $277.00Low
1/11/2023Robert W. BairdBoost TargetOutperform$270.00 ➝ $285.00Low
1/6/2023Morgan StanleyBoost TargetOverweight$290.00 ➝ $303.00Low
12/12/2022CitigroupDowngradeBuy ➝ Neutral$275.00 ➝ $250.00Low
11/23/2022Credit Suisse GroupLower TargetOutperform$308.00 ➝ $305.00Low
11/3/2022MizuhoLower TargetBuy$296.00 ➝ $250.00Low
10/31/2022Morgan StanleyLower TargetOverweight$300.00 ➝ $290.00Low
10/28/2022Truist FinancialLower TargetBuy$275.00 ➝ $260.00Low
10/28/2022CitigroupLower Target$300.00 ➝ $275.00Low
10/28/2022Robert W. BairdLower Target$297.00 ➝ $270.00Low
10/27/2022William BlairReiterated RatingOutperformLow
9/19/2022ArgusDowngradeBuy ➝ HoldLow
8/22/2022Morgan StanleyReiterated RatingOverweight$300.00Low
8/9/2022Credit Suisse GroupLower Target$308.00Low
8/4/2022Robert W. BairdBoost TargetOutperform$295.00 ➝ $297.00Low
8/1/2022Credit Suisse GroupLower TargetOutperform$312.00 ➝ $308.00Low
5/25/2022Morgan StanleyLower TargetOverweight$360.00 ➝ $300.00Low
5/4/2022MizuhoLower Target$354.00 ➝ $323.00Low
5/3/2022Deutsche Bank AktiengesellschaftLower Target$294.00 ➝ $265.00Low
5/2/2022Credit Suisse GroupLower Target$344.00 ➝ $312.00Medium
4/29/2022Truist FinancialLower Target$350.00 ➝ $320.00Low
4/25/2022Wells Fargo & CompanyLower TargetEqual Weight$290.00 ➝ $235.00Medium
2/14/2022Morgan StanleyLower TargetOverweight$380.00 ➝ $360.00Low
2/11/2022Wells Fargo & CompanyLower Target$340.00 ➝ $320.00High
2/11/2022Credit Suisse GroupBoost TargetOutperform$340.00 ➝ $344.00High
2/11/2022CitigroupBoost Target$340.00 ➝ $350.00High
1/28/2022Deutsche Bank AktiengesellschaftDowngradeBuy ➝ Hold$330.00 ➝ $294.00High
12/20/2021MizuhoBoost TargetBuy$332.00 ➝ $354.00Low
12/17/2021Morgan StanleyBoost TargetOverweight$377.00 ➝ $380.00Low
12/14/2021Wells Fargo & CompanyBoost TargetOverweight ➝ Overweight$330.00 ➝ $340.00Medium
11/1/2021Credit Suisse GroupBoost TargetOutperform$336.00 ➝ $338.00Low
10/29/2021Morgan StanleyBoost TargetOverweight$368.00 ➝ $377.00Low
8/31/2021Morgan StanleyBoost TargetOverweight$273.00 ➝ $368.00Low
8/20/2021Credit Suisse GroupBoost TargetOutperform$295.00 ➝ $336.00Low
8/19/2021MizuhoBoost TargetBuy$318.00 ➝ $332.00Medium
7/30/2021Truist FinancialBoost TargetPositive ➝ Buy$330.00 ➝ $350.00Low
7/30/2021Deutsche Bank AktiengesellschaftBoost TargetBuy$297.00 ➝ $330.00Medium
7/30/2021MizuhoBoost TargetBuy$310.00 ➝ $318.00Medium
7/21/2021Robert W. BairdSet TargetBuy$276.78Low
5/20/2021ArgusBoost TargetAverage ➝ Buy$270.00 ➝ $295.00Medium
5/12/2021MizuhoBoost TargetBuy$267.00 ➝ $310.00Low
5/3/2021Truist FinancialBoost Target$300.00 ➝ $320.00Low
5/3/2021CitigroupBoost Target$278.00 ➝ $312.00Low
5/3/2021Jefferies Financial GroupBoost TargetBuy$300.00 ➝ $310.00Low
4/14/2021Truist FinancialBoost TargetAbove Average ➝ Buy$280.00 ➝ $300.00Medium
4/1/2021Jefferies Financial GroupReiterated RatingBuyHigh
2/12/2021CitigroupBoost TargetBuy$257.00 ➝ $278.00Low
2/12/2021JPMorgan Chase & Co.Boost TargetOverweight$261.00 ➝ $279.00Low
2/12/2021MizuhoBoost TargetBuy$242.00 ➝ $267.00Low
1/29/2021CitigroupBoost TargetBuy$249.00 ➝ $257.00Low
1/14/2021MizuhoBoost TargetBuy$234.00 ➝ $242.00Low
1/11/2021ArgusUpgradeHold ➝ Buy$245.00Medium
1/8/2021Wolfe ResearchDowngradeOutperform ➝ Peer PerformHigh
10/28/2020Wells Fargo & CompanyBoost TargetOverweight$225.00 ➝ $260.00Low
10/28/2020MizuhoBoost TargetBuy$215.00 ➝ $234.00Low
10/27/2020William BlairReiterated RatingOutperformLow
10/14/2020Jefferies Financial GroupBoost TargetBuy$183.00 ➝ $230.00Low
7/31/2020MizuhoBoost TargetBuy$186.00 ➝ $215.00Low
7/29/2020Bank of AmericaBoost TargetBuy$220.00 ➝ $240.00Medium
7/29/2020SunTrust BanksBoost TargetPositive ➝ Buy$220.00 ➝ $240.00Medium
7/29/2020Deutsche Bank AktiengesellschaftBoost TargetBuy$210.00 ➝ $230.00Medium
7/29/2020CitigroupBoost TargetBuy$214.00 ➝ $249.00Medium
7/14/2020Bank of AmericaUpgradeNeutral ➝ Buy$194.00 ➝ $220.00High
7/13/2020Wolfe ResearchUpgradePeer Perform ➝ Outperform$202.00 ➝ $217.00High
6/10/2020Wells Fargo & CompanyReiterated RatingBuyMedium
6/8/2020Robert W. BairdBoost TargetOutperform$199.00 ➝ $219.00Medium
6/4/2020JPMorgan Chase & Co.Boost TargetOverweight$118.00 ➝ $223.00Medium
6/2/2020Deutsche Bank AktiengesellschaftInitiated CoverageBuy$210.00Medium
5/21/2020SunTrust BanksBoost TargetBuy$200.00 ➝ $220.00Medium
5/20/2020Morgan StanleyBoost TargetOverweight$241.00 ➝ $244.00Low
5/15/2020MizuhoUpgradeNeutral ➝ Buy$158.00 ➝ $186.00Low
5/5/2020UBS GroupBoost TargetBuy$209.00 ➝ $218.00Low
4/30/2020JPMorgan Chase & Co.Boost Target$149.00 ➝ $188.00Medium
4/30/2020Morgan StanleyBoost TargetOverweight$172.00 ➝ $241.00Medium
4/30/2020Bank of AmericaBoost TargetNeutral$147.00 ➝ $190.00Medium
4/29/2020KeyCorpDowngradeOverweight ➝ Sector WeightMedium
4/27/2020Wolfe ResearchUpgradeUnderperform ➝ Market Perform$188.00Medium
4/27/2020CitigroupUpgradeNeutral ➝ Buy$204.00 ➝ $214.00High
4/23/2020BarclaysBoost TargetOverweight$188.00 ➝ $195.00Medium
4/16/2020MizuhoLower TargetNeutral$163.00 ➝ $158.00Medium
4/13/2020SunTrust BanksLower TargetBuy$225.00 ➝ $200.00Medium
4/8/2020Morgan StanleyLower TargetOverweight$211.00 ➝ $172.00High
4/2/2020JPMorgan Chase & Co.Lower TargetOverweight$182.00 ➝ $149.00Medium
3/30/2020Wells Fargo & CompanyLower TargetOverweight$215.00 ➝ $170.00Medium
3/30/2020KeyCorpLower TargetOverweight$212.00 ➝ $170.00High
3/26/2020BarclaysLower TargetOverweight$212.00 ➝ $188.00Low
3/24/2020JPMorgan Chase & Co.Lower TargetOverweight$204.00 ➝ $182.00High
2/25/2020MizuhoBoost TargetNeutral$174.00 ➝ $190.00High
2/18/2020Morgan StanleyBoost TargetOverweight$199.00 ➝ $211.00Medium
2/14/2020Evercore ISIInitiated CoverageBuy$215.00Medium
2/14/2020CitigroupBoost TargetNeutral$179.00 ➝ $204.00Low
2/13/2020Piper SandlerBoost Target$177.00 ➝ $219.00Low
1/7/2020Wells Fargo & CompanyInitiated CoverageOverweight$210.00High
1/3/2020Bank of AmericaDowngradeNeutral ➝ UnderperformLow
10/21/2019UBS GroupLower TargetBuy$204.00 ➝ $200.00Low
8/23/2019Morgan StanleyBoost TargetOverweight$190.00 ➝ $201.00Medium
8/8/2019KeyCorpBoost TargetOverweight$172.00 ➝ $192.00Medium
7/26/2019Morgan StanleyBoost TargetOverweight$175.00 ➝ $190.00High
7/16/2019Bank of AmericaUpgradeUnderperform ➝ Neutral$174.60Low
7/15/2019BarclaysSet TargetBuy$200.00Low
6/20/2019Deutsche Bank AktiengesellschaftUpgradeHold ➝ Buy$180.00 ➝ $220.00High
5/20/2019MizuhoBoost TargetNeutral$150.00 ➝ $174.00Low
5/1/2019CitigroupBoost TargetNeutral ➝ Neutral$157.00 ➝ $176.00Low
5/1/2019UBS GroupBoost TargetBuy ➝ Buy$178.00 ➝ $195.00Low
(Data available from 4/12/2019 forward)

News Sentiment Rating

0.94 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 19 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
  • 23 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 4 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 8 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 19 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 24 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 2 very negative mentions
  • 34 very positive mentions
  • 22 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
  • 26 very positive mentions
  • 19 positive mentions
  • 0 negative mentions
  • 1 very negative mentions

Current Sentiment

  • 26 very positive mentions
  • 19 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Laboratory Co. of America logo
Laboratory Corporation of America Holdings operates as a life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. It operates in two segments, Labcorp Diagnostics (Dx) and Biopharma Laboratory Services (BLS). The company offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, PAP tests, hemoglobin A1C and vitamin D, prostate-specific antigens, tests for sexually transmitted diseases, hepatitis C tests, microbiology cultures and procedures, and alcohol and other substance-abuse tests. It also provides specialty testing services comprising gene-based and esoteric testing; advanced tests target specific diseases; services related to anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, parentage and donor testing, occupational testing services, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests; and health and wellness services to employers and managed care organizations (MCOs), including health fairs, on-site and at-home testing, vaccinations, and health screenings. In addition, the company offers online and mobile applications that enable patients to check test results; online applications for providers, MCOs, and accountable care organizations; and drug development, medical device, and companion diagnostic development solutions from early-stage research to clinical development, as well as support for crop protection and chemical testing. It serves pharmaceutical, biotechnology, medical device, and diagnostics companies; and MCOs, employer plans, other health insurance providers, governmental agencies, physicians and other healthcare providers, hospitals and health systems, employers, patients and consumers, contract research organizations, crop protection and chemical companies, academic institutions, independent clinical laboratories, and retailers. The company was incorporated in 1994 and is headquartered in Burlington, North Carolina.
Read More

Today's Range

Now: $205.73
Low: $204.40
High: $206.40

50 Day Range

MA: $215.83
Low: $205.73
High: $228.11

52 Week Range

Now: $205.73
Low: $174.20
High: $234.09


715,528 shs

Average Volume

738,565 shs

Market Capitalization

$17.31 billion

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of Laboratory Co. of America?

The following sell-side analysts have issued stock ratings on Laboratory Co. of America in the last year: Argus, Bank of America Co., Barclays PLC, Citigroup Inc., Credit Suisse Group AG, Deutsche Bank Aktiengesellschaft, Evercore ISI, HSBC Holdings plc, JPMorgan Chase & Co., Leerink Partnrs, Mizuho, Morgan Stanley, Robert W. Baird,, SVB Leerink LLC, TheStreet, Truist Financial Co., UBS Group AG, and Wells Fargo & Company.
View the latest analyst ratings for LH.

What is the current price target for Laboratory Co. of America?

16 Wall Street analysts have set twelve-month price targets for Laboratory Co. of America in the last year. Their average twelve-month price target is $243.50, suggesting a possible upside of 18.4%. Wells Fargo & Company has the highest price target set, predicting LH will reach $270.00 in the next twelve months. HSBC Holdings plc has the lowest price target set, forecasting a price of $210.00 for Laboratory Co. of America in the next year.
View the latest price targets for LH.

What is the current consensus analyst rating for Laboratory Co. of America?

Laboratory Co. of America currently has 3 hold ratings and 11 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for LH.

What other companies compete with Laboratory Co. of America?

Other companies that are similar to Laboratory Co. of America include Quest Diagnostics, Exact Sciences, Natera, Avantor and Hologic. Learn More about companies similar to Laboratory Co. of America.

How do I contact Laboratory Co. of America's investor relations team?

Laboratory Co. of America's physical mailing address is 358 South Main Street, BURLINGTON NC, 27215. The medical research company's listed phone number is (336) 229-1127 and its investor relations email address is [email protected]. The official website for Laboratory Co. of America is Learn More about contacing Laboratory Co. of America investor relations.